What's new? Log in Free sign up

Filing search / Iovance Biotherapeutics, Inc. / "Mission"

Search information

Iovance Biotherapeutics, Inc.

Companies

"Mission"

Keywords

SEC filings

Source

Export list of results

Export a CSV file of filings or unique companies (up to first 5,000 results).

Download list of filings Download list of companies

34 results

Newest first Best match first

IOVA Iovance Biotherapeutics, Inc.

diverse cancer cells using therapies personalized for each patient. Our mission is to be the global leader in innovating, developing, and delivering tumor … , developing, and delivering TIL cell therapy Our mission is to be the global leader in innovating, developing, and delivering TIL cell therapy

27 Feb 25

5:15pm

IOVA Iovance Biotherapeutics, Inc.

mission of PHS includes proper data management and appropriate data sharing as described in the “NIH Policy for Data Management and Sharing” (DMS

27 Feb 25

5:15pm

IOVA Iovance Biotherapeutics, Inc.

Quarterly report

patient. The Company’s mission is to be the global leader in innovating, developing and delivering tumor infiltrating lymphocyte (“TIL”) cell therapies … mission is to be the global leader in innovating, developing and delivering tumor infiltrating lymphocyte, or TIL, cell therapies for patients with solid

7 Nov 24

5:15pm

IOVA Iovance Biotherapeutics, Inc.

Quarterly report

system’s ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The Company’s mission is to be the global … immune system’s ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. Our mission is to be the global

8 Aug 24

5:10pm

IOVA Iovance Biotherapeutics, Inc.

Quarterly report

by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The Company’s mission … for each patient. Our mission is to be the global leader in innovating, developing and delivering tumor infiltrating lymphocyte, or TIL, cell

9 May 24

5:10pm

Definitive proxy

29 Apr 24

5:06pm

28 Feb 24

5:15pm

Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2023

Prospectus supplement for primary offering

Quarterly report

7 Nov 23

5:15pm

ttht8f3 idcyt2nr

Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2023

Quarterly report

8 Aug 23

5:15pm

Iovance Biotherapeutics Reports Second Quarter and First Half 2023

et8r8 cpeclxwd8wzr

Prospectus supplement for primary offering

Prospectus supplement for primary offering

Prospectus supplement for primary offering

Automatic shelf registration

Iovance Biotherapeutics Announces U.S. Food and Drug Administration

Quarterly report

10 May 23

4:30pm

rio1617z3fqn 04

Definitive proxy

26 Apr 23

5:15pm

Prev
1
2
Next

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.